FDA Decision On Interchangeable Exclusivity Allows Pfizer To Rival Boehringer On Adalimumab
Humira Biosimilar Abrilada Is Now Interchangeable; Pfizer Reveals Launch And Pricing Details
An FDA decision around the timing of first interchangeable biosimilar exclusivity has brought to an end Boehringer Ingelheim’s time on the market with a unique interchangeable Humira rival, with the agency also granting interchangeability for Pfizer’s Abrilada version of adalimumab.
